drugset / Trial / NCT05304455
Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to determine whether Apixaban is effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients after Laparoscopic Splenectomy and Azygoportal Disconnection
Timeline
- Start
- 2022-04-01
- Primary completion
- 2023-05-31
- Completion
- 2023-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apixaban | Small molecule | 2.5 mg | Oral |
| Background | Dipyridamole | Other / unclassified | 25 mg | Oral |